Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...

Under the settlement, Mainers who are uninsured or have commercial health insurance will be eligible to purchase monthly ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

and in its Q3 results Sanofi said US revenues from Lantus were down 15.5% in the quarter to $1.123 billion. Admelog has also been approved in Europe as a biosimilar under the name Insulin lispro ...

It's been two years since Pharmaniaga Bhd slipped into Practice Note 17 (PN17) status. Will the company's regularisation plan ...

At present no reports on glulisine use in pregnancy are available. [53] Insulin Glargine. The first long-acting insulin analogue was approved for clinical use in patients with Type 1 and Type 2 ...

28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension ...

In July 2003. the company launched Lantus, the worlds first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.In the year 2004 ...